Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases

2019 ◽  
Vol 72 ◽  
pp. 169-182 ◽  
Author(s):  
Hee Jae Huh ◽  
Su-Young Kim ◽  
Byung Woo Jhun ◽  
Sung Jae Shin ◽  
Won-Jung Koh
2020 ◽  
Vol 26 (36) ◽  
pp. 4658-4674 ◽  
Author(s):  
Christina Kannigadu ◽  
David. D. N'Da

: Infectious diseases commonly occur in tropical and sub-tropical countries. The pathogens of such diseases are able to multiply in human hosts, warranting their continual survival. Infections that are commonplace include malaria, chagas, trypanosomiasis, giardiasis, amoebiasis, toxoplasmosis and leishmaniasis. Malaria is known to cause symptoms, such as high fever, chills, nausea and vomiting, whereas chagas disease causes enlarged lymph glands, muscle pain, swelling and chest pain. People suffering from African trypanosomiasis may experience severe headaches, irritability, extreme fatigue and swollen lymph nodes. As an infectious disease progresses, the human host may also experience personality changes and neurologic problems. If left untreated, most of these diseases can lead to death. : Parasites, microbes and bacteria are increasingly adapting and generating strains that are resistant to current clinical drugs. Drug resistance creates an urgency for the development of new drugs to treat these infections. Nitro containing drugs, such as chloramphenicol, metronidazole, tinidazole and secnidazole had been banned for use as antiparasitic agents due to their toxicity. However, recent discoveries of nitrocontaining anti-tuberculosis drugs, i.e. delamanid and pretonamid, and the repurposing of flexinidazole for use in combination with eflornithine for the treatment of human trypanosomiasis, have ignited interest in nitroaromatic scaffolds as viable sources of potential anti-infective agents. : This review highlights the differences between old and new nitration methodologies. It furthermore offers insights into recent advances in the development of nitroaromatics as anti-infective drugs.


2020 ◽  
Vol 5 (1) ◽  
pp. 49-66 ◽  
Author(s):  
Léonard Bezinge ◽  
Akkapol Suea-Ngam ◽  
Andrew J. deMello ◽  
Chih-Jen Shih

This account reviews the major amplification strategies utilizing nanomaterials in electrochemical biosensing for robust and sensitive molecular diagnostics.


2011 ◽  
Vol 1807 (6) ◽  
pp. 735-745 ◽  
Author(s):  
Inthrani R. Indran ◽  
Grégory Tufo ◽  
Shazib Pervaiz ◽  
Catherine Brenner

2021 ◽  
Vol 3 (12) ◽  
pp. 247-251
Author(s):  
Xichao Ou ◽  
◽  
Hui Xia ◽  
Shengfen Wang ◽  
Bing Zhao ◽  
...  

Molecules ◽  
2019 ◽  
Vol 24 (21) ◽  
pp. 3886 ◽  
Author(s):  
Lee ◽  
Kim ◽  
Hayat ◽  
Shin

Parasitic diseases have serious health, social, and economic impacts, especially in the tropical regions of the world. Diseases caused by protozoan parasites are responsible for considerable mortality and morbidity, affecting more than 500 million people worldwide. Globally, the burden of protozoan diseases is increasing and is been exacerbated because of a lack of effective medication due to the drug resistance and toxicity of current antiprotozoal agents. These limitations have prompted many researchers to search for new drugs against protozoan parasites. In this review, we have compiled the latest information (2012–2017) on the structures and pharmacological activities of newly developed organic compounds against five major protozoan diseases, giardiasis, leishmaniasis, malaria, trichomoniasis, and trypanosomiasis, with the aim of showing recent advances in the discovery of new antiprotozoal drugs.


2020 ◽  
Vol 27 ◽  
Author(s):  
Wen Li ◽  
Reham M. Elhassan ◽  
Xuben Hou ◽  
Hao Fang

: The PROTAC (PROteolysis TArgeting Chimera) technology is a target protein degradation strategy, based on the ubiquitin-proteasome system, which has been gradually developed into a potential means of targeted cancer therapy in recent years. This strategy has already shown significant advantages over traditional small-molecule inhibitors in terms of pharmacodynamics, selectivity, and drug resistance. Several small molecule PROTACs have been in a Phase I clinical trial. Herein, we introduced the mechanism, characteristics, and advantages of PROTAC strategy. And we summarize the recent advances in the development of small-molecule PROTACs for cancer treatment. We hope this review will be helpful in optimizing the design of the ideal small-molecule PROTACs and advancing targeted anticancer research.


2015 ◽  
Vol 15 (6) ◽  
pp. 801-813 ◽  
Author(s):  
Mattia Boeri ◽  
Stefano Sestini ◽  
Orazio Fortunato ◽  
Carla Verri ◽  
Paola Suatoni ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document